<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03632135</url>
  </required_header>
  <id_info>
    <org_study_id>CG01GBM</org_study_id>
    <nct_id>NCT03632135</nct_id>
  </id_info>
  <brief_title>Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma</brief_title>
  <acronym>CSCRGBM</acronym>
  <official_title>Standard Chemotherapy Versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Glioblastoma Multiforme (GBM).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordgenics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordgenics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to confirm the utility of chemosensitivity tumor
      testing on cancer stem cells (ChemoID) as a predictor of clinical response in poor prognosis
      malignant brain tumors such as recurrent glioblastoma (GBM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a parallel group randomized controlled clinical trial to determine
      if recurrent Glioblastoma (GBM) patients treated with drugs predicted by the ChemoID assay
      will have better outcomes than patients treated with standard-of-care control therapy chosen
      by the Physician.

      Upon obtaining informed consent, all eligible participants affected by recurrent GBM will
      have a tumor biopsy to undergo ChemoID drug response testing with multiple FDA-approved
      chemotherapeutic agents.

      Eligible participants will be randomized to a standard treatment arm with control treatment
      (chemotherapy chosen by the Physician from a provided list), or to a study arm of
      FDA-approved drugs selected by the ChemoID drug response assay.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>parallel group randomized controlled clinical trial</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Study investigators will be kept blind to the schedule. All participants will be screened by the ChemoID drug response assay; however, the treating physician will receive the ChemoID results only for those participants who are randomized to ChemoID-guided treatment arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Median Overall Survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>Overall survival (OS) in recurrent GBM patients who have had a ChemoID assay-guided treatment compared to standard therapy chosen by the physician.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at 6, 9, and 12 months (OS6mo, OS9mo, OS12mo)</measure>
    <time_frame>6, 9, and 12 months</time_frame>
    <description>Overall survival at 6, 9, and 12 months in recurrent GBM patients who have had a ChemoID assay-guided treatment compared to standard therapy chosen by the physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression Free Survival (PFS)</measure>
    <time_frame>36 months</time_frame>
    <description>Median Progression Free Survival in recurrent GBM patients who have had a ChemoID assay-guided treatment compared to standard therapy chosen by the physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival at 4, 6, 9, and 12 months (PFS4mo, PFS6mo, PFS9mo, PFS12mo)</measure>
    <time_frame>4, 6, 9, and 12 months</time_frame>
    <description>Progression Free survival at 4, 6, 9, and12 months in recurrent GBM patients who have had a ChemoID assay-guided treatment compared to standard therapy chosen by the physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Tumor Response</measure>
    <time_frame>36 months</time_frame>
    <description>Objective tumor response measured by RANO (Response Assessment in Neuro-oncology Criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>36 months</time_frame>
    <description>Health-Related Quality of Life questionnaire (HRQOL)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Recurrent Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Physician Choice treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be treated with control chemotherapy treatment (standard-of-care chemotherapy chosen by the Physician from the provided list).
Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:
Carboplatin;
Irinotecan;
Etoposide;
BCNU;
CCNU;
Temozolomide;
Procarbazine;
Vincristine;
Imatinib;
Procarbazine, CCNU, Vincristine;
Carboplatin, Irinotecan;
Carboplatin, Etoposide;
Temozolomide, Etoposide;
Temozolomide, Imatinib. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ChemoID-guided treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated with ChemoID-guided standard-of-care chemotherapy drugs from the provided list.
ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:
Carboplatin;
Irinotecan;
Etoposide;
BCNU;
CCNU;
Temozolomide;
Procarbazine;
Vincristine;
Imatinib;
Procarbazine, CCNU, Vincristine;
Carboplatin, Irinotecan;
Carboplatin, Etoposide;
Temozolomide, Etoposide;
Temozolomide, Imatinib.
The treating physician will receive the ChemoID assay results from the ChemoID lab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ChemoID assay</intervention_name>
    <description>The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.
The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse.</description>
    <arm_group_label>ChemoID-guided treatment</arm_group_label>
    <arm_group_label>Physician Choice treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent ovarian cancer</description>
    <arm_group_label>ChemoID-guided treatment</arm_group_label>
    <arm_group_label>Physician Choice treatment</arm_group_label>
    <other_name>Cytotoxic chemotherapy drugs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Men and Women and members of all ethnic groups who are at least 18 years old at the
             time of enrollment are eligible for this trial;

          -  2. Informed consent obtained and signed;

          -  3. Willing and able to commit to study procedures including long-term follow-up
             visit(s);

          -  4. Histopathologically confirmed WHO grade IV recurrent glioblastoma (GBM).

          -  5. In all cases, the diagnosis must be confirmed by a pathologist.

          -  6. Recurrent surgically resectable tumor and/or biopsy;

          -  7. Participants who have undergone surgical resection should have received an MRI or a
             scan after surgery in order to visualize residual tumor. If not, the operative report
             must be available;

          -  8. Start of radiotherapy, if indicated, must occur at least 2 weeks after surgery
             and/or biopsy;

          -  9. Estimated survival of at least 3 months;

          -  10. Hgb &gt; 9 gm; absolute neutrophil count (ANC) &gt; 1500/Î¼l; platelets &gt; 100,000;
             Creatinine &lt; 1.5 times the upper limit of laboratory normal value; Bilirubin &lt; 2 times
             the upper limit of laboratory normal value; serum glutamate pyruvate transaminase
             (SGPT) or serum glutamate oxaloacetate transaminase (SGOT) &lt; 3 times the upper limit
             of laboratory normal value;

          -  11. If indicated radiation therapy and chemotherapy must start within 8 weeks of tumor
             resection or biopsy.

        Exclusion Criteria:

          -  1. Subjects with newly diagnosed GBM

          -  2. Pregnant women or nursing mothers cannot participate in the study. Women of
             childbearing age must have a negative pregnancy test within 72 hours prior to study
             entry. Women of childbearing potential must practice medically approved contraceptive
             precautions;

          -  3. Abnormal hematological results at inclusion with: Neutrophils &lt; 1,500/mm3;
             Blood-platelets &lt; 100,000/mm3

          -  4. Severe or chronic renal insufficiency (creatinine clearance â¤ 30 ml/min);

          -  5. Patient unable to follow procedures, visits, examinations described in the study;

          -  6. Any usual formal indication against imaging examinations (important claustrophobia,
             pacemaker);
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tulika Ranjan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allegheny Health Network</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tulika Ranjan, MD</last_name>
    <phone>412-359-3748</phone>
    <email>Tulika.RANJAN@ahn.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Ohm, BS</last_name>
    <phone>412-359-8162</phone>
    <email>Sara.Ohm@AHN.ORG</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Green, MD</last_name>
      <phone>323-783-4011</phone>
      <email>Sandra.T.Baker@kp.org</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Baker-Bolden</last_name>
      <phone>(323) 783-5532</phone>
      <email>Sandra.T.Baker@kp.org</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Green, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Mammoser, MD</last_name>
      <phone>504-568-2698</phone>
      <email>amammo@lsuhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Ensminger, RN</last_name>
      <phone>504-568-2507</phone>
      <email>mensmi@lsuhsc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Aaron Mammoser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center Research Institute</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Lu-Emerson, MD</last_name>
      <email>CLuEmerson@mmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Logan Ahmann, CCRP</last_name>
      <phone>207-396-8377</phone>
      <email>LAhmann@mmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Christine Lu-Emerson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark D. Anderson, MD</last_name>
      <phone>601-984-5517</phone>
      <email>manderson4@umc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Barnes, RHIA, CCRP</last_name>
      <phone>601-815-4550</phone>
      <email>jbarnes@umc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Garden State Neurology and Neuro-oncology</name>
      <address>
        <city>West Long Branch</city>
        <state>New Jersey</state>
        <zip>07764</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samul N Raval, MD</last_name>
      <phone>732-229-6200</phone>
      <email>Drraval@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kaitlyn Reiff, APN</last_name>
      <phone>732-229-6200</phone>
      <email>kaitlynreiff@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Samul Raval, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Cancer Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soma Sengupta, MD, PhD</last_name>
      <phone>513-558-5457</phone>
      <email>sengupsm@ucmail.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cathy Bailey</last_name>
      <phone>513-558-8195</phone>
      <email>baileyca@ucmail.uc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Soma Sengupta, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toledo University</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Schroeder, MD</last_name>
      <phone>419-383-4000</phone>
      <email>Jason.Schroeder5@UToledo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Smiddy, RN,CCRC</last_name>
      <phone>419-383-6962</phone>
      <email>stephanie.smiddy@UToledo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Schroeder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center Oncology</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyla Lindberg, RN, BSN</last_name>
      <phone>503-216-1191</phone>
      <email>Kyla.Lindberg@Providence.org</email>
    </contact>
    <contact_backup>
      <last_name>Rick Chen, MD</last_name>
      <email>Ricky.Chen2@providence.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ricky Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's University Health Network</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gavinski Megan</last_name>
      <phone>484-503-4157</phone>
      <email>Megan.Gavinski@sluhn.org</email>
    </contact>
    <contact_backup>
      <last_name>Hugh Moulding, MD</last_name>
      <email>Hugh.moulding@sluhn.org</email>
    </contact_backup>
    <investigator>
      <last_name>Hugh Moulding, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Penn State Univeristy College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawit Aregawi, MD</last_name>
      <phone>717-531-3828</phone>
      <email>daregawi@PennStateHealth.psu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Scott Stanley, MS</last_name>
      <phone>717-531-0003</phone>
      <phone_ext>285799</phone_ext>
      <email>sstanley2@pennstatehealth.psu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dawit Aregawi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospitals</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Glass, MD</last_name>
      <phone>215-955-9797</phone>
      <email>jon.glass@jefferson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Schultz, CRC</last_name>
      <phone>215-955-5891</phone>
      <email>Elizabeth.Schultz@jefferson.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jon Glass, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Health Network</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tulika Ranjan, MD</last_name>
      <phone>412-770-3039</phone>
      <email>Tulika.RANJAN@ahn.org</email>
    </contact>
    <contact_backup>
      <last_name>Sara Ohm, BS</last_name>
      <phone>412-359-8162</phone>
      <email>Sara.Ohm@AHN.ORG</email>
    </contact_backup>
    <investigator>
      <last_name>Tulika Ranjan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charleston Area Medical Center</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25326</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Jubelirer, MD</last_name>
      <phone>304-388-8380</phone>
      <email>steven.jubelirer@camc.org</email>
    </contact>
    <contact_backup>
      <last_name>Augusta Kosowicz, PA-C, CCRC</last_name>
      <phone>304-388-9940</phone>
      <email>augusta.kosowicz@camc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Steven Jubelirer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Howard CM, Valluri J, Alberico A, Julien T, Mazagri R, Marsh R, Alastair H, Cortese A, Griswold M, Wang W, Denning K, Brown L, Claudio PP. Analysis of Chemopredictive Assay for Targeting Cancer Stem Cells in Glioblastoma Patients. Transl Oncol. 2017 Apr;10(2):241-254. doi: 10.1016/j.tranon.2017.01.008. Epub 2017 Feb 12.</citation>
    <PMID>28199863</PMID>
  </results_reference>
  <results_reference>
    <citation>Tulika Ranjan, Candace M. Howard, Jagan Valluri, Alexander Yu, Khaled Aziz, David Jho, Terrence Julien, Jody Leonardo, Anthony Alberico, Antonio Cortese, Krista Denning, and Pier Paolo Claudio. Prospective Analysis of Cancer Stem Cell Drug Response Assay for Glioblastoma Patients. J Clin Oncol 36, 2018 (suppl; abstr 2057) - ASCO Annual Meeting, Chicago, June 1-5, 2018.</citation>
  </results_reference>
  <results_reference>
    <citation>Candace M Howard, Anthony Alberico, Jagan Valluri, Michael Griswold, and Pier Paolo Claudio. Analysis of chemo-predictive assay for targeting cancer stem cells in 41 glioblastoma patients. Journal of Clinical Oncology 2017 35:15_suppl, e13544-e13544</citation>
  </results_reference>
  <results_reference>
    <citation>Pier Paolo Claudio, Sarah E Mathis, Rounak Nande, Anthony Alberico, Walter Neto, Logan Lawrence, James Denvir, Gerrit A. Kimmey, Aneel A. Chowdhary, Maria R. B. Tria Tirona, Mark Jeffrey Mogul, Terrence D Julien, Rida S Mazagri, Gerald Oakley, Krista L Denning, Thomas Dougherty, Linda Brown, and Jagan Valluri. Novel chemosensitivity assay for targeting cancer stem-like cells in brain tumors. Journal of Clinical Oncology 2014 32:15_suppl, e13012-e13012</citation>
  </results_reference>
  <results_reference>
    <citation>Ranjan T, Howard CM, Yu A, Xu L, Aziz K, Jho D, Leonardo J, Hameed MA, Karlovits SM, Wegner RE, Fuhrer R, Lirette ST, Denning KL, Valluri J, Claudio PP. Cancer Stem Cell Chemotherapeutics Assay for Prospective Treatment of Recurrent Glioblastoma and Progressive Anaplastic Glioma: A Single-Institution Case Series. Transl Oncol. 2020 Apr;13(4):100755. doi: 10.1016/j.tranon.2020.100755. Epub 2020 Mar 17.</citation>
    <PMID>32197147</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ChemoID</keyword>
  <keyword>Cancer stem cells</keyword>
  <keyword>Drug response assay</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Brain Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

